Antibody humanisation
We can help you humanise your antibodies with a success rate of more than 98%.
With many promising antibodies developed in non-human formats, humanisation is a vital step on the journey to the clinic.
Our team can help you humanise monoclonal antibodies from a wide range of species, including mice, hamsters, rats, rabbits, chickens and camelids, producing therapeutic candidate molecules of various modalities including VHH, IgG, Fab and VH-Fc.
We work closely with you throughout the process and ask for no upfront fee – instead, we receive a small royalty on sales.
Why work with us?
Over the past 30 years, we’ve helped to humanise nearly 100 therapeutic monoclonal antibodies, including contributing to 5 licensed drugs.
No upfront payment
We take on the developmental risk, so you don’t have to. Instead of an upfront fee, we receive a small royalty on sales after market approval is secured.
Driven by impact, not profit
We work on projects with strong scientific rationale, clear routes to commercialisation and the greatest potential for patient impact.
Transparent collaboration
We work closely with you throughout the project, with open dialogue and regular sharing of samples for evaluation. You retain IP ownership and control after the project ends.
More than 98% success rate
We produce as many candidates as we need – we don’t limit ourselves to a fixed number – and have experience with a diverse range of target classes.
Exceptional antibody quality
Lead antibodies have optimal expression levels and binding, stability and biophysical characteristics. Most display a binding level at least 95% that of the chimeric protein.
Swift delivery and valuable support
Expect humanised antibodies in around 6 months. We can also support you post-delivery with publication, patent support, and guidance on further development.
Our collaborative approach
- No upfront payment – we take on the developmental risk so you don’t have to.
- LifeArc receives a small royalty on sales after market approval has been secured.
- We also consider other deal structures where appropriate.
Our track record
30
years of experience
94
antibodies humanised
51
companies served worldwide
98%
success rate
Humanised antibodies for 5 licensed drugs
Who to contact
-
Preeti Bakrania
Read bio: Preeti Bakrania
Other ways we can support you
Antibody discovery
Innovative single B-cell technologies and clinically-validated platform to generate fully human therapeutic antibodies.
Diagnostics development
We support all stages of diagnostic development, from assay design through to clinical validation.
Targeted protein degradation
PROTACs and alternative E3 ligases to degrade target proteins that aren’t classically targetable by small molecule inhibitors.
Commercialisation advice
Support your technology transfer to progress your work towards commercially viable products.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email info@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
Latest news
-
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya -
LifeArc supports 8 new fellows through Crick Africa Network (CAN) partnership
Read more: LifeArc supports 8 new fellows through Crick Africa Network (CAN) partnership